Literature DB >> 12130481

Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms.

Robert A S Ariëns1, Thung-Shenq Lai, John W Weisel, Charles S Greenberg, Peter J Grant.   

Abstract

Factor XIII and fibrinogen are unusual among clotting factors in that neither is a serine protease. Fibrin is the main protein constituent of the blood clot, which is stabilized by factor XIIIa through an amide or isopeptide bond that ligates adjacent fibrin monomers. Many of the structural and functional features of factor XIII and fibrin(ogen) have been elucidated by protein and gene analysis, site-directed mutagenesis, and x-ray crystallography. However, some of the molecular aspects involved in the complex processes of insoluble fibrin formation in vivo and in vitro remain unresolved. The findings of a relationship between fibrinogen, factor XIII, and cardiovascular or other thrombotic disorders have focused much attention on these 2 proteins. Of particular interest are associations between common variations in the genes of factor XIII and altered risk profiles for thrombosis. Although there is much debate regarding these observations, the implications for our understanding of clot formation and therapeutic intervention may be of major importance. In this review, we have summarized recent findings on the structure and function of factor XIII. This is followed by a review of the effects of genetic polymorphisms on protein structure/function and their relationship to disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12130481     DOI: 10.1182/blood.v100.3.743

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  72 in total

1.  Evidence that αC region is origin of low modulus, high extensibility, and strain stiffening in fibrin fibers.

Authors:  John R Houser; Nathan E Hudson; Lifang Ping; E Timothy O'Brien; Richard Superfine; Susan T Lord; Michael R Falvo
Journal:  Biophys J       Date:  2010-11-03       Impact factor: 4.033

2.  Factor XIII Val34Leu polymorphism and gamma-chain cross-linking at the site of microvascular injury in healthy and coumadin-treated subjects.

Authors:  A Undas; B Brzezinska-Kolarz; K Brummel-Ziedins; J Musial; A Szczeklik; K G Mann
Journal:  J Thromb Haemost       Date:  2005-09       Impact factor: 5.824

3.  Impact of FXIII-A Val34Leu polymorphism on coronary artery disease in Croatian patients.

Authors:  Ana Bronić; Goran Ferencak; Renata Zadro; Ana Stavljenić-Rukavina; Robert Bernat
Journal:  Mol Biol Rep       Date:  2007-09-27       Impact factor: 2.316

4.  Direct evidence for specific interactions of the fibrinogen alphaC-domains with the central E region and with each other.

Authors:  Rustem I Litvinov; Sergiy Yakovlev; Galina Tsurupa; Oleg V Gorkun; Leonid Medved; John W Weisel
Journal:  Biochemistry       Date:  2007-07-13       Impact factor: 3.162

5.  Antagonistic enzymes may generate alternate phase transitions leading to ephemeral gels.

Authors:  Sébastien Giraudier; Véronique Larreta-Garde
Journal:  Biophys J       Date:  2007-04-27       Impact factor: 4.033

Review 6.  Fibrin gels and their clinical and bioengineering applications.

Authors:  Paul A Janmey; Jessamine P Winer; John W Weisel
Journal:  J R Soc Interface       Date:  2009-01-06       Impact factor: 4.118

7.  Temporal and spatial patterning of transgene expression by near-infrared irradiation.

Authors:  Francisco M Martin-Saavedra; Virginia Cebrian; Leyre Gomez; Daniel Lopez; Manuel Arruebo; Christopher G Wilson; Renny T Franceschi; Richard Voellmy; Jesus Santamaria; Nuria Vilaboa
Journal:  Biomaterials       Date:  2014-06-21       Impact factor: 12.479

8.  EGF potentiated oncogenesis requires a tissue transglutaminase-dependent signaling pathway leading to Src activation.

Authors:  Bo Li; Marc A Antonyak; Joseph E Druso; Le Cheng; Alexander Yu Nikitin; Richard A Cerione
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

9.  Pharmacodynamics and pharmacokinetics of oral contraceptives co-administered with alosetron (Lotronex).

Authors:  Kevin Koch; Corinne Campanella; Charlotte A Baidoo; Janet A Manzo; Vanessa Z Ameen; Kathryn E E Kersey
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

10.  Fibrin architecture in clots: a quantitative polarized light microscopy analysis.

Authors:  Peter Whittaker; Karin Przyklenk
Journal:  Blood Cells Mol Dis       Date:  2008-12-02       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.